GI-6301 is GlobeImmune’s third oncology Tarmogen® product to begin human clinical trials LOUISVILLE, Colo., Feb. 8, 2012 – GlobeImmune, Inc. today announced the initiation of a Phase 1 clinical trial to be conducted at the National Cancer Institute (NCI) to … Continue reading
GlobeImmune Initiates Phase 1 Clinical Trial of GI-6301 in Brachyury Expressing Cancers
February 08, 2012